Curacle has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase 2b clinical trial of CU06, its oral treatment candidate for retinal diseases, in patients with diabetic macular edema (DME), the company said Friday.
CU06, whose generic name is rivasterat, is an orally administered endothelial dysfunction blocker developed using Curacle's proprietary technology. It is a first-in-class drug candidate designed to improve blood vessel barrier function and protect retinal nerve cells.
The main treatment for retinal diseases currently involves injecting anti-vascular endothelial growth factor (anti-VEGF) drugs directly into the eye to block VEGF signaling.
Because these conditions often require long-term treatment, patients may experience anxiety about eye injections, as well as pain and discomfort afterward. Repeated hospital visits also impose time and financial burdens. This has created an unmet medical need for oral treatments that reduce the burden of administration and help patients maintain consistent treatment.
Curacle previously completed a Phase 2a trial involving 67 patients with diabetic macular edema at 11 clinical trial centers in the United States. In a subgroup analysis of patients whose best-corrected visual acuity (BCVA) was 69 letters or lower before treatment, those who received a 300-milligram dose of CU06 showed an average improvement of about six letters after 12 weeks.
Curacle designed the Phase 2b trial to focus on patients with poor vision, the subgroup that showed more pronounced improvement in the Phase 2a trial.
The study will involve 156 patients with central retinal swelling and BCVA scores of 25 to 69 letters on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart. Participants will be randomly assigned to receive 200 mg of CU06, 300 mg of CU06 or a placebo once daily for 24 weeks.
The primary endpoint will be the change in BCVA from baseline at Week 24, which will be used to assess CU06's vision improvement effects compared with the placebo.
Curacle refined its follow-up development strategy through a Type C meeting with the FDA last year. The trial will be conducted by Syneos Health, a global contract research organization with extensive experience in clinical trials in the retinal disease field.
Alongside the Phase 2b trial of CU06, Curacle plans to pursue further research on multiple drug candidates and seek business opportunities through technology transfers.
In May, the company licensed MT-103, a preclinical bispecific antibody candidate for retinal diseases, to U.S.-based Memento Medicines. It is also continuing research on antibody drug candidates MT-101, MT-201 and MT-202, as well as developing follow-up small-molecule drug candidates CU72 and CU73.
"Through the Phase 2b trial, we plan to more closely verify the vision improvement effects and safety observed in Phase 2a and determine the appropriate dose for a Phase 3 trial," a Curacle official said. "We will do our best to offer a new oral treatment option for patients who find repeated eye injections burdensome."